Markers of beta cell and alpha cell mass in human stem cell-generated implants with glycemic control at human setpoint
Stem Cells Translational Medicine · 20.07.2026 · 15 (8)
DOI: 10.1093/stcltm/szag068 ↗Kurz gefasst
Fachartikel in der Zeitschrift Stem Cells Translational Medicine, online erschienen am 14.08.2026. Verfasst von Kaat De Groot und 9 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Pathology & Therapy, Vrije Universiteit Brussel, 1090, Brussels, Belgium. Hauptthemen laut MEDLINE: Insulin-Secreting Cells, Glucagon-Secreting Cells, Glycemic Control, Stem Cells. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Research Foundation-Flanders.
Abstract (Originalsprache)
Human stem cell (SC)-generated beta cell implants represent a potential cure for type 1 diabetes. Studies in rodents and patients showed that they can establish a glucose-regulated source of insulin in recipients with depleted pancreatic beta cell mass. Their therapeutic significance is, however, determined by their capacity to restore glycemic control by the human glucostat. It is so far unknown which implant characteristics are needed for this key endpoint. The present study addresses this question in mice. SC-derived preparations with a defined beta cell dose and alpha cell proportion were implanted in the epididymal fat pad of normoglycemic SCID/beige mice (mouse glucostat basal glycemia 166 mg/dL). At post-transplant week 20, 12/25 recipients reached glycemic control at the human glucostat (glycemia ≤ 90 mg/dL) following a time-dependent increase of basal and glucose-induced plasma human C-peptide and decrease of mouse C-peptide towards under detection limit. Formation of their functional human beta cell mass was preceded by formation of a human alpha cell mass that became the source for circulating glucagon and a contributor to glycemic control. The insulin content of the implants reached the values in the pancreas of control mice and were thus identified as in situ markers for implants that established the glycemic endpoint. Co-existence with a functional alpha cell mass places alpha cell formation as a potential additional component for achieving the goal. Our study also demonstrates the relevance of using normoglycemic mice to assess stem cell therapy protocols for beta cell replacement.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Diabetes Pathology & Therapy, Vrije Universiteit Brussel, 1090, Brussels, Belgium.
- Diabetes Clinic, Universitair Ziekenhuis Brussel, 1090, Brussels, Belgium.
- Department of Surgery, Universitair Ziekenhuis Brussel, 1090, Brussels, Belgium.
- ViaCyte Inc, San Diego, CA, CA 92121, United States.
ORCID-Profile: Kaat De Groot, Krista Suenens, Geert Stangé, Diedert De Paep, Eline Segers, Evert Kroon, Bart Keymeulen, Daniel Jacobs-Tulleneers-Thevissen, Daniel Pipeleers
Förderung
- Research Foundation-Flanders
Zitieren
APA
De Groot, K., Suenens, K., Stangé, G., Ling, Z., De Paep, D., Segers, E., Kroon, E., Keymeulen, B., Jacobs-Tulleneers-Thevissen, D., & Pipeleers, D. (2026). Markers of beta cell and alpha cell mass in human stem cell-generated implants with glycemic control at human setpoint. Stem Cells Translational Medicine, 15(8). https://doi.org/10.1093/stcltm/szag068
Vancouver
De Groot K, Suenens K, Stangé G, Ling Z, De Paep D, Segers E, et al. Markers of beta cell and alpha cell mass in human stem cell-generated implants with glycemic control at human setpoint. Stem Cells Translational Medicine. 2026;15(8). doi:10.1093/stcltm/szag068
BibTeX
@article{DeGroot2026,
author = {De Groot, Kaat and Suenens, Krista and Stangé, Geert and Ling, Zhidong and De Paep, Diedert and Segers, Eline and Kroon, Evert and Keymeulen, Bart and Jacobs-Tulleneers-Thevissen, Daniel and Pipeleers, Daniel},
title = {Markers of beta cell and alpha cell mass in human stem cell-generated implants with glycemic control at human setpoint},
journal = {Stem Cells Translational Medicine},
year = {2026},
volume = {15},
number = {8},
doi = {10.1093/stcltm/szag068}
}
EUVIMED